A5075171633- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Pancreatitis Pathology and Treatment
- Frailty in Older Adults
Central University Hospital of Asturias
2023-2024
Universidad de Oviedo
2023
The prognostic value of the Systemic Inflammation Response Index (SIRI) in advanced pancreatic cancer is recognized, but its correlation with patients´ nutritional status and outcomes remains unexplored.
Abstract Introduction The initial SARS-CoV-2 pandemic wave in Spain 2020 precipitated significant paradigm shifts gastrointestinal oncology patient management. This study captures the “Zeitgeist” of this period by analyzing adaptive strategies, treatment modifications, and survival outcomes, leveraging a 3-year follow-up perspective to extract insights from unprecedented experience. Methods We conducted multicenter, retrospective cohort utilizing RETUD-TTD registry, encompassing 703 patients...
623 Background: Whilethe systemic inflammatory response assessed by SIRI has been recognized as a prognostic factor in advanced pancreatic cancer, understanding its association with patients' nutritional status may provide deeper insights into disease biology and outcomes. Methods: This is an observational, non-interventional multicenter study (15 Spanish hospitals) promoted SEOM, including retrospective prospectively patients metastatic cancer routine clinical practice. Clinical data was...
<h3>Background and Importance</h3> There is no standard first-line regimen for HER2-negative advanced gastroesophageal adenocarcinoma. <h3>Aim Objectives</h3> To study the variability in choice of regimens according to tumour, patient baseline variables prescribing physician. <h3>Material Methods</h3> Patients with adenocarcinoma diagnosed between 2008 2021 from a multicentre registry (34 centres) were included. received chemotherapy based on platinum (cisplatin or oxaliplatin)...